Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter
The University of Texas Health Science Center at San Antonio · Fred Hutch Cancer Center · +8 more institutions
Abstract
The optimal upper limit of the normal range for prostate-specific antigen (PSA) is unknown. We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or less.
Of 18,882 men enrolled in the prevention trial, 9459 were randomly assigned to receive placebo and had an annual measurement of PSA and a digital rectal examination. Among these 9459 men, 2950 men never had a PSA level of more than 4.0 ng per milliliter or an abnormal digital rectal examination, had a final PSA determination, and underwent a prostate biopsy after being in the study for seven years.
Citation impact
- FWCI
- 119.03
- Percentile
- 100%
- References
- 30
Authors
12- IMIan M. ThompsonCorresponding
The University of Texas Health Science Center at San Antonio
- DKDonna K. Pauler
Fred Hutch Cancer Center, Cancer Research Center, Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
- PJPhyllis J. Goodman
Cancer Research Center, Fred Hutch Cancer Center, Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
- CMCatherine M. Tangen
Cancer Research Center, Fred Hutch Cancer Center, Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
- MSM. Scott Lucia
University of Colorado Denver, University of Colorado Health, University of Colorado Hospital
Topics & keywords
- Medicine
- Liter
- Rectal examination
- Prostate cancer
- Prostate
- Prostate-specific antigen
- Urology
- Cancer
- Good health and well-being